A window of opportunity for no treatment in early multiple sclerosis?

Abstract

Get full access to this article

View all access options for this article.

References

Jacobs LD , Beck RW , Simon JH , et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.

Comi G. , Filippi M. , Barkhof F. , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.

Kappos L. , Polman CH , Freedman MS , et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.

Comi G. , Martinelli V. , Rodegher M. , et al. Effect of glatiramer acetate on conversion to clinically defi nite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.

Kappos L. , Freedman MS , Polman CH , et al. Long-term eff ect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997.

Paty DW , Li DKB. for the IFNB Multiple Sclerosis Study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-667.

Jacobs LD , Cookfair DL , Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.

European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.

10.

Johnson KP , Brooks BR , Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: Results of a phase III multi-center, double- blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.

11.

Bjartmar C. , Kinkel RP , Kidd G. , Rudick RA , Trapp BD Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001 ; 57: 1248-1252.

12.

The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis, final optic neuritis treatment trial follow-up. Arch Neurol 2008 ; 65: 727-732.

13.

Fisniku LK , Brex PA , Altmann DR , et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.

14.

Scolding N. , Wilkins A. , Cottrell D. New guidelines for MS treatment - no cause for celebration. Adv Clin Neurosci Rehabil 2007; 7: 17-18.

15.

Ebers GC , Heigenhauser L. , Daumer M. , Lederer C. , Noseworthy JH Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624-631.

16.

Liu C. , Blumhardt LD Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000 ; 68: 450-457.

17.

PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.

18.

Schwid SR , Bever CT The cost of delaying treatment in multiple sclerosis: What is lost is not regained. Neurology 2001; 56: 1620.

19.

Kinkel RP , Kollman C. , O’Connor P. , et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.

20.

Kinkel RP , Tanner JP , Simon J. , O’Connor P. , Kollmann C. CHAMPIONS Extension study: 10-year follow-up after a clinically isolated syndrome in high risk patients. Neurology 2009; 72(11, S3): P06-137.

21.

Kappos L. , Freedman MS , Polman CH , et al. BENEFIT 3 year data Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397.

22.

Filippi M. , Rovaris M. , Inglese M. , et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.

23.

Daumer M. , Neuhaus A. , Morrissey S. , Hintzen R. , Ebers GC MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72: 705-711.

24.

Freedman M. ‘ Time is brain ’ also in multiple sclerosis . Mult Scler 2009; 15: 1133-1134.